ACOG Stock Forecast & Price Target

Alpha Cognition is attractive because ZUNVEYL is demonstrating clear differentiation from generic AChEIs through materially better tolerability and real-world benefit, with BEACON showing reported cognitive improvement in 92% of patients, neuropsychiatric improvement in 93%, and favorable GI tolerability. Commercial execution is also strengthening, as 2Q26 bottle dispensing rose to 8,294 from 6,054 in 1Q26, prescribing HCPs increased to 1,347 from 1,060, and 1,095 long-term care facilities generated prescriptions, while Medicare Part D contracts now cover approximately 45 million lives. The balance sheet and cost structure further support the outlook, with $41.4M in cash at mid-2026, a ~$6.1M settlement reducing future royalty burdens, and a sublingual formulation plus ongoing studies such as CONVERGE and RESOLVE offering additional upside to long-term market expansion.

Alpha Cognition is fundamentally challenged by heavy dependence on ZUNVEYL, with valuation resting on an assumed $540M peak annual U.S. sales base that remains unproven and execution-sensitive. The DCF framework itself implies only $500M to $580M of enterprise value using a 12% discount rate and a 3% terminal rate of decline, while fully diluted shares are expected to rise from ~28M by end-2026 to ~29M by end-1Q27 and mid-2027, highlighting dilution pressure. Its outlook is further weakened by the stated risks of slow sales traction, pricing and payor push-back, competition from generic and branded products, and clinical setbacks, all of which could prevent timely commercialization of ZUNVEYL.